Skip to Content

Celebrex (celecoxib) - Dec 21, 2004

Audience: Rheumatologists and other healthcare professionals

FDA notified healthcare professionals that, based on emerging information, including preliminary reports from one of several long term National Institutes of Health (NIH) prevention studies, the risk of cardiovascular events may be increased in patients receiving Celebrex. FDA is analyzing all available information from these studies to determine whether additional regulatory action is needed.

[December 17, 2004 - Drug Information Page - FDA]

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.